Abstract
MicroRNAs are short non-coding molecules that play a major role in regulating gene expression. Peripheral levels of miR-1202 have been shown to predict and mediate antidepressant response. However, it is not clear to what extent these peripheral measures reflect central neural changes in vivo. We approached this problem with the combined use of peripheral miR-1202 measures and neuroimaging. At baseline and after 8 weeks of desvenlafaxine (50–100 mg die), 20 patients were scanned with 3T magnetic resonance imaging, first at rest then during the Go/NoGo task, a classical test of response inhibition. Blood samples were collected at both time points. During resting state, lower baseline miR-1202 levels were predictive of increased connectivity from T0 to T8 between the posterior cingulate and the prefrontal, parietal, and occipital cortices. Changes in miR-1202 levels following desvenlafaxine treatment were negatively correlated with changes in activity in right precuneus within the default-mode network, and in connectivity between the posterior cingulate and the temporal and prefrontal cortices, and the precuneus. During the Go/NoGo task, baseline miR-1202 levels and changes in these levels were correlated with activity changes in different regions, including bilateral prefrontal, insular, cingulate, and temporal cortices, and left putamen and claustrum. Finally, secondary analyses in a subset of patients showed a trend for a significant correlation between miR-1202 levels and glutamate levels measured by spectroscopy. Changes in peripheral miR-1202 levels were therefore associated with changes in brain activity and connectivity in a network of brain regions associated with depression and antidepressant response. These effects may be mediated by the glutamatergic system.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Balthazar ML, Pereira FR, Lopes TM, da Silva EL, Coan AC, Campos BM et al (2014). Neuropsychiatric symptoms in Alzheimer’s disease are related to functional connectivity alterations in the salience network. Hum Brain Mapp 35: 1237–1246.
Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O (2010). miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329: 1537–1541.
Beckmann CF, Smith SM (2004). Probabilistic independent component analysis for functional magnetic resonance imaging. IEEE Trans Med Imaging 23: 137–152.
Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D et al (2013). Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol 23: 602–611.
Chen H, Wang N, Burmeister M, McInnis MG (2009). MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol 12: 975–981.
Cox RW (2012). AFNI: what a long strange trip it’s been. Neuroimage 62: 743–747.
Cruceanu C, Lopez JP, Tsai WT, Turecki G (2016). Dysregulation of the glutamatergic receptors after antidepressant treatment in human neural progenitor cells. Mol Psychiatry (epub ahead of print).
Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P (2011). Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord 130: 66–74.
Dichter GS, Gibbs D, Smoski MJ (2015). A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. J Affect Disord 172: 8–17.
Duncan NW, Wiebking C, Tiret B, Marjanska M, Hayes DJ, Lyttleton O et al (2013). Glutamate concentration in the medial prefrontal cortex predicts resting-state cortical-subcortical functional connectivity in humans. PLoS One 8: e60312.
Dutta A, McKie S, Deakin JF (2014). Resting state networks in major depressive disorder. Psychiatry Res 224: 139–151.
First MB, Spitzer RL, Gibbon M, Williams JBW (2012) Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I), Clinician Version, Administration Booklet. American Psychiatric Publishing: New York.
Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ (2008). A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 29: 683–695.
Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J et al (2004). Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 61: 877–889.
Fu CH, Costafreda SG, Sankar A, Adams TM, Rasenick MM, Liu P et al (2015). Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine. BMC Psychiatry 15: 82.
Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N et al (2008). Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148.
Gray AL, Hyde TM, Deep-Soboslay A, Kleinman JE, Sodhi MS (2015). Sex differences in glutamate receptor gene expression in major depression and suicide. Mol Psychiatry 20: 1057–1068.
Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
Iglesias JE, Liu CY, Thompson PM, TU Z (2011). Robust brain extraction across datasets and comparison with publicly available methods. IEEE Trans Med Imaging 30: 1617–1634.
Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R et al (2014). MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 83: 344–360.
Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM (2012). FSL. Neuroimage 62: 782–790.
Jollant F, Richard-Devantoy S, Ding Y, Turecki G, Bechara A, Near J (2016). Prefrontal inositol levels and implicit decision-making in healthy individuals and depressed patients. Eur Neuropsychopharmacol 26: 1255–1263.
Kaiser S, Unger J, Kiefer M, Markela J, Mundt C, Weisbrod M (2003). Executive control deficit in depression: event-related potentials in a Go/Nogo task. Psychiatry Res 122: 169–184.
Lau MA, Christensen BK, Hawley LL, Gemar MS, Segal ZV (2007). Inhibitory deficits for negative information in persons with major depressive disorder. Psychol Med 37: 1249–1259.
Lopez JP, Lim R, Cruceanu C, Crapper L, Fasano C, Labonte B et al (2014). miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med 20: 764–768.
Lorenz RC, Gleich T, Buchert R, Schlagenhauf F, Kühn S, Gallinat J (2015). Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum. Hum Brain Mapp 36: 4031–4040.
Mellios N, Huang HS, Grigorenko A, Rogaev E, Akbarian S (2008). A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontalcortex. Hum Mol Genet 17: 3030–3042.
Mulders PC, van Eijndhoven PF, Schene AH, Beckmann CF, Tendolkar I (2015). Resting-state functional connectivity in major depressive disorder: a review. Neurosci Biobehav Rev 56: 330–344.
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197–2223.
Murrough JW, Abdallah CG, Anticevic A, Collins KA, Geha P, Averill LA et al (2016). Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Hum Brain Mapp 37: 3214–3223.
O’Connor RM, Dinan TG, Cryan JF (2012). Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol Psychiatry 17: 359–376.
Oldfield RC (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9: 97–113.
Pereira FR, Alessio A, Sercheli MS, Pedro T, Bilevicius E, Rondina JM et al (2010). Asymetricla hippocampal connectivity in mesial temporal lobe epilepsy: evidence from resting state fMRI. BMC Neurosci 11: 66.
Phillips ML, Chase HW, Sheline YI, Etkin A, Almeida JR, Deckersbach T et al (2015). Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 172: 124–138.
Richard-Devantoy S, Ding Y, Lepage M, Turecki G, Jollant F (2016). Cognitive inhibition in depression and suicidal behavior: a neuroimaging study. Psychol Med 46: 933–944.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905–1917.
Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z et al (2004). Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 22: 409–418.
Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD (2012). Decoding subject-driven cognitive states with whole-brain connectivity patterns. Cereb Cortex 22: 158–165.
Vaisvaser S, Modai S, Farberov L, Lin T, Sharon H, Gilam A et al (2016). Neuro-epigenetic indications of acute stress response in humans: the case of microRNA-29c. PLoS One 11: e0146236.
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654–659.
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13: 423–433.
Xu C, Liu X, Song X, Gao Q, Cheng L, Wang L et al (2016). Aberrant resting state in microRNA-30e rat model of cognitive impairment. Neuroreport 27: 809–817.
Zhang X, Tang Y, Maletic-Savatic M, Sheng J, Zhang X, Zhu Y et al (2016). Altered neuronal spontaneous activity correlates with glutamate concentration in medial prefrontal cortex of major depressed females: an fMRI-MRS study. J Affect Disord 201: 153–161.
Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y et al (2009). Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34: 1395–1405.
Acknowledgements
We would like to thank Mrs Iliana Lilova for her role in patient recruitment, and M Yang Ding for his role in neuroimaging data acquisition and storing.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Lopez, J., Pereira, F., Richard-Devantoy, S. et al. Co-Variation of Peripheral Levels of miR-1202 and Brain Activity and Connectivity During Antidepressant Treatment. Neuropsychopharmacol 42, 2043–2051 (2017). https://doi.org/10.1038/npp.2017.9
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2017.9
This article is cited by
-
Epigenetic mechanisms of rapid-acting antidepressants
Translational Psychiatry (2024)
-
Stress, microRNAs, and stress-related psychiatric disorders: an overview
Molecular Psychiatry (2023)
-
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential
Signal Transduction and Targeted Therapy (2023)
-
The important roles of microRNAs in depression: new research progress and future prospects
Journal of Molecular Medicine (2021)
-
Neural extracellular vesicle-derived miR-17 in blood as a potential biomarker of subthreshold depression
Human Cell (2021)
